Immunotherapy has emerged in recent years as a new cancer treatment that is gentler than traditional chemotherapy and causes milder side effects in patients. However, conventional dendritic cell (DC) immunotherapy shows inconsistent clinical outcomes, and the cell culture process remains complex and costly.
